Publication:
Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.

dc.contributor.authorPastor-Villaescusa, Belen
dc.contributor.authorCañete, M Dolores
dc.contributor.authorCaballero-Villarraso, Javier
dc.contributor.authorHoyos, Raul
dc.contributor.authorLatorre, Miriam
dc.contributor.authorVazquez-Cobela, Rocio
dc.contributor.authorPlaza-Diaz, Julio
dc.contributor.authorMaldonado, Jose
dc.contributor.authorBueno, Gloria
dc.contributor.authorLeis, Rosaura
dc.contributor.authorGil, Angel
dc.contributor.authorCañete, Ramon
dc.contributor.authorAguilera, Concepcion M
dc.contributor.funderSpanish Ministry of Health, Social and Equality, General Department for Pharmacy and Health Products
dc.date.accessioned2023-01-25T09:49:48Z
dc.date.available2023-01-25T09:49:48Z
dc.date.issued2017-03-21
dc.description.abstractMetformin has shown its effectiveness in treating obesity in adults. However, little research has been conducted in children, with a lack of attention on pubertal status. The objectives were to determine whether oral metformin treatment reduces BMI z score, cardiovascular risk, and inflammation biomarkers in children who are obese depending on pubertal stage and sex. This was a randomized, prospective, double-blind, placebo-controlled, multicenter trial, stratified according to pubertal stage and sex, conducted at 4 Spanish clinical hospitals. Eighty prepubertal and 80 pubertal nondiabetic children who were obese aged 7 to 14 years with a BMI >95th percentiles were recruited. The intervention included 1 g/d of metformin versus placebo for 6 months. The primary outcome was a reduction in BMI z score. Secondary outcomes comprised insulin resistance, cardiovascular risk, and inflammation biomarkers. A total of 140 children completed the study (72 boys). Metformin decreased the BMI z score versus placebo in the prepubertal group (-0.8 and -0.6, respectively; difference, 0.2; P = .04). Significant increments were observed in prepubertal children treated with metformin versus placebo recipients in the quantitative insulin sensitivity check index (0.010 and -0.007; difference, 0.017; P = .01) and the adiponectin-leptin ratio (0.96 and 0.15; difference, 0.81; P = .01) and declines in interferon-γ (-5.6 and 0; difference, 5.6; P = .02) and total plasminogen activator inhibitor-1 (-1.7 and 2.4; difference, 4.1; P = .04). No serious adverse effects were reported. “Metformin decreased the BMI z score and improved inflammatory and cardiovascular-related obesity parameters only in prepubertal children, but a differential effect of metformin was not observed in prepubertal compared to pubertal children. Nevertheless, the doses per kilogram of weight administrated may have had an impact on the metformin effect. Further investigations are necessary.”
dc.description.versionSi
dc.identifier.citationPastor-Villaescusa B, Cañete MD, Caballero-Villarraso J, Hoyos R, Latorre M, Vázquez-Cobela R, et al. Metformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial. Pediatrics. 2017 Jul;140(1):e20164285. doi: 10.1542/peds.2016-4285. Epub 2017 Jun 12. Erratum in: Pediatrics. 2017 Nov;140(5):e20172555
dc.identifier.doi10.1542/peds.2016-4285
dc.identifier.essn1098-4275
dc.identifier.pmid28759403
dc.identifier.urihttp://hdl.handle.net/10668/11457
dc.issue.number1
dc.journal.titlePediatrics
dc.language.isoen
dc.organizationHospital Universitario Reina Sofía
dc.organizationInstituto Maimónides de Investigación Biomédica de Córdoba-IMIBIC
dc.organizationHospital Universitario Virgen de las Nieves
dc.page.number10
dc.provenanceRealizada curación de contenido 21/01/2025
dc.publisherAmerican Academy of Pediatrics
dc.pubmedtypeJournal Article
dc.relation.publisherversionhttps://publications.aap.org/pediatrics/article-lookup/doi/10.1542/peds.2016-4285
dc.rights.accessRightsRestricted Access
dc.subjectAdolescent
dc.subjectBiomarkers
dc.subjectBody mass index
dc.subjectCardiovascular diseases
dc.subject.decsMetformina
dc.subject.decsObesidad infantil
dc.subject.decsÍndice de masa corporal (IMC)
dc.subject.decsMarcadores de inflamación
dc.subject.decsRiesgo cardiovascular
dc.subject.meshChild
dc.subject.meshDouble-blind method
dc.subject.meshFemale
dc.subject.meshHumans
dc.subject.meshInflammation
dc.subject.meshMale
dc.subject.meshMetformin
dc.subject.meshPediatric obesity
dc.subject.meshProspective studies
dc.subject.meshPuberty
dc.subject.meshSex factors
dc.titleMetformin for Obesity in Prepubertal and Pubertal Children: A Randomized Controlled Trial.
dc.typeresearch article
dc.volume.number140
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
RISalud_Accesorestringido.pdf
Size:
93.39 KB
Format:
Adobe Portable Document Format